Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Administration of AdVEGF-All6A+ to Myocardium of Individuals With Diffuse CAD Via Minimally Invasive Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01757223
Recruitment Status : Not yet recruiting
First Posted : December 28, 2012
Last Update Posted : February 24, 2020
Sponsor:
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
The proposed Phase I/II clinical trial will be used to determine the safety and toxicity of direct administration of the vector AdVEGF-All6A+ to the ischemic myocardium and to generate preliminary evidence regarding whether direct administration of AdVEGF-All6A+ to the ischemic myocardium will induce growth of collateral blood vessels and improve cardiac function. This is a three-part, multinational/multi-center, placebo controlled study.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Biological: AdVEGF-All6A+ Biological: AdNull Phase 1 Phase 2

Detailed Description:
Coronary artery disease (CAD) is the predominant cause of heart failure, a major cause of death and disability throughout the world. Although prognosis of patients with CAD has been greatly improved by advances in cardiovascular treatment, it is still the first cause of death in the USA. Treatment options for CAD include diet, exercise, medication, balloon angioplasty with or without stenting, atherectomy and bypass surgery. For many patients, however, the disease is diffuse and stenting or bypass surgery is not an option. A new strategy to treat these patients is to use gene therapy to induce new networks of new blood vessels to bypass the arterial system that is blocked, thus providing circulation to deliver oxygen needed by the tissue. By administering a gene coding for vascular endothelial growth factor (VEGF) to the myocardium, new networks of blood vessels can be created using the genetic material for VEGF. In experimental animal studies, VEGF is effective at treating ischemia of organs and is safe. The most direct method of transferring genes to myocardium is by injection under direct vision during a minimally invasive thoracic surgery. For the present study, the VEGF gene will be delivered to the myocardium using a modified adenovirus (Ad) as a carrier. The study is designed to test the safety and efficacy of AdVEGF-All6A+.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 41 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase I/II Study, Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human Vascular Endothelial Growth Factor to the Ischemic Myocardium...
Estimated Study Start Date : December 2020
Estimated Primary Completion Date : October 2030
Estimated Study Completion Date : October 2030

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part A, Group 1 - 10^8 pu
Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^8 particle units.
Biological: AdVEGF-All6A+
We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.

Experimental: Part A, Group 2 - 10^9 pu
Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^9 particle units.
Biological: AdVEGF-All6A+
We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.

Experimental: Part A, Group 3 - 10^10 pu
Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^10 particle units.
Biological: AdVEGF-All6A+
We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.

Experimental: Part B, Group 1 - AdVEGF-All6A+
Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 1 will receive AdVEGF-All6A+ at the highest tolerable dose determined in Part A.
Biological: AdVEGF-All6A+
We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.

Experimental: Part B, Group 2 - AdNull placebo
Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 2 will receive AdNull, the placebo vector.
Biological: AdNull
AdNull is an adenovirus vector identical to AdVEGF-All6A+, except that it does not encode for a transgene.




Primary Outcome Measures :
  1. Time to 1 mm ST depression during exercise-stress testing [ Time Frame: 3 mos (Part A); 6 mos (Part B) ]
    Collect the times during the stress-test


Secondary Outcome Measures :
  1. Exercise-stress echocardiogram [ Time Frame: Twice before vector administration at -30 days and -15 days (± 5 days), and will be repeated at day 90 post-vector for Part A and day 90 and 180 post-vector for Part B ]
    To assess segmental wall motion in treated territories

  2. Angina [ Time Frame: Twice pre-vector administration at -30 days and -15 days, and repeated at 30 and 90 days post-vector for Part A and at 30, 90 and 180 days post-vector for Part B ]
    measured by the Canadian Cardiovascular Society Functional Classification of Angina Pectoris

  3. Cardiac MRI +/- adenosine stress [ Time Frame: Once pre-vector and repeated at 90 days post vector for Part A, and 180 days post-vector for Part B ]
    To assess segmental wall motion and perfusion in treated territories



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and females, age 18 to 90
  • Demonstrable reversible left ventricular ischemia in viable myocardium as assessed by ST segment/T wave abnormalities detected by exercise testing with 99mTc-sestamibi single-photon emission computed tomography (SPECT) prior to and following the exercise test
  • Individuals who have coronary artery disease (CAD) but have angina refractory to medical therapy
  • Individuals who experience angina class II-IV as defined by the Canadian Cardiovascular Society
  • Individuals who have had a coronary angiogram in the prior 6 months demonstrating diffuse coronary artery disease and are not considered to be eligible for coronary artery bypass surgery, stents, or angioplasty, because of the lack of suitable target lesions
  • Individuals must be medically capable of undergoing open thoracotomy
  • Individuals must have neutralizing anti-adenovirus serotype 5 titer ≤160; this criteria is based on the knowledge that some individuals have high anti Ad5 neutralizing antibody titer which may limit efficacy
  • Hematocrit >30%
  • WBC <10,000
  • Normal prothrombin, partial thromboplastin time (excluding IV heparin therapy)
  • Normal liver-related serum parameters
  • Glomerular filtration rate (GFR) > 30 ml/min
  • No evidence of active infection of any types, including adenovirus, hepatitis virus (A, B or C) or human immunodeficiency virus
  • No evidence of central nervous system, major psychiatric, musculoskeletal or immune disorder
  • No allergy to the vehicle used to suspend the virus or contrast materials used in radiographic procedures
  • Fertile or infertile individuals; it will be recommended that fertile individuals utilize barrier birth control measures to prevent pregnancy during and for 2 months following the administration of the vector
  • Individuals not receiving experimental medications or participating in another experimental protocol for at least 4 weeks prior to entry to the study.
  • Individuals must be able to exercise for at least 90 seconds but no more than 15 min on a modified Bruce protocol exercise treadmill test while exhibiting angina with concurrent 1 mm horizontal or downsloping ST-segment depression
  • The study individual must be able to undergo the procedures in the protocol
  • Willingness to participate in the study
  • Capable of providing informed consent

Exclusion Criteria:

  • Individuals who do not meet the inclusion criteria will be unable to participate in the protocol
  • Individuals in whom participation in the study would compromise the normal care and expected progression of their disease
  • Individuals receiving corticosteroids or other immunosuppressive medications
  • Individuals with uncontrolled diabetes
  • Diabetic individuals with significantly abnormal ophthalmologic exam (moderate or greater disease severity)
  • Individuals with hypercholesterolemia (LDL above 190 mg/dl or total cholesterol above 240 mg/dl)
  • Body mass index >35
  • Recent (<6 wk) cerebral vascular accident
  • Recent (<6 wk) transmural myocardial infarction
  • Evidence of infection defined by elevated white blood cell (WBC) count, temperature >38.5ºC, infiltrate on chest x-ray
  • Unable to undergo cardiac MRI with gadolinium contrast
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values 2.5 greater than normal limits
  • Prior cardiac transplantation
  • Electrocardiograph abnormalities that would interfere with ST-segment analysis
  • Untreated malignant ventricular arrhythmia
  • Valvular heart disease requiring surgical intervention
  • Preoperative congestive heart failure (New York Heart Association Function Class III or IV or ejection fraction (EF) <25%
  • Uncontrollable asthma or chronic obstructive pulmonary disease (COPD)
  • Greater than first degree heart block or sinus node dysfunction without a functional pacemaker
  • Systolic blood pressure less than 90 mmHg
  • Known hypersensitivity to adenosine
  • Pregnancy or currently lactating
  • Prior participation in cardiac gene and/or cardiac cell therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01757223


Contacts
Layout table for location contacts
Contact: Grace W Mammen, BA, CCRP 646-962-2672 gwm2004@med.cornell.edu

Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Layout table for investigator information
Principal Investigator: Ronald G Crystal, MD Weill Medical College of Cornell University
Layout table for additonal information
Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT01757223    
Other Study ID Numbers: 1204012330
1201-1145 ( Other Identifier: Recombinant DNA Advisory Commitee )
First Posted: December 28, 2012    Key Record Dates
Last Update Posted: February 24, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Weill Medical College of Cornell University:
Diffuse Coronary Artery Disease (CAD)
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases